Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8624578rdf:typepubmed:Citationlld:pubmed
pubmed-article:8624578lifeskim:mentionsumls-concept:C0042071lld:lifeskim
pubmed-article:8624578lifeskim:mentionsumls-concept:C0024623lld:lifeskim
pubmed-article:8624578lifeskim:mentionsumls-concept:C0030190lld:lifeskim
pubmed-article:8624578lifeskim:mentionsumls-concept:C0030191lld:lifeskim
pubmed-article:8624578lifeskim:mentionsumls-concept:C0032145lld:lifeskim
pubmed-article:8624578lifeskim:mentionsumls-concept:C0220901lld:lifeskim
pubmed-article:8624578lifeskim:mentionsumls-concept:C2347946lld:lifeskim
pubmed-article:8624578pubmed:issue5lld:pubmed
pubmed-article:8624578pubmed:dateCreated1996-6-25lld:pubmed
pubmed-article:8624578pubmed:abstractTextExpression of urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2) was evaluated in 125 surgically resected gastric cancers by immunohistochemical analysis. Tissue was stained immunohistochemically with a monoclonal antibody against human uPA and monoclonal antibodies against human PAI-1 and PAI-2. In addition, DNA ploidy patterns were determined by cytofluorometer after staining with propidium iodide. We found that 82 (66%) of the 125 gastric cancers expressed uPA as diffuse cytoplasmic staining, as intensely outlined luminal borders. PAI-1 expression was observed in 62 (50%) of 125 gastric cancer as a fine, diffuse and granular pattern in the cytoplasm. PAI-2 expression was observed in 65 (52%) of the 125 gastric cancers as a diffuse cytoplasmic staining. uPA-positive tumours showed a higher incidence of infiltration, lymph node metastasis and peritoneal dissemination that uPA-negative ones. Patients with uPA-positive tumours proved to have a significantly poorer prognosis than those with negative ones. PAI-1-negative tumours showed a higher incidence of liver metastasis and carried a poorer prognosis than PAI-1-positive ones. There was no significant correlation between uPA or PAI-1 expression and DNA ploidy patterns. Conversely, there was no significant relationship between PAI-2 expression and clinicopathological parameters and prognosis. According to the expression of uPA and PAI-1 status, groups of 19 uPA(-)/PAI-1(-), 44 uPA(+)/PAI-1(-), 23 uPA(-)/PAI-1(+) and 39 uPA(+)/PAI-1(+) were subdivided. Tumours with uPA(+)/PAI-1(-) had a significantly higher incidence of liver metastasis, lymph node metastasis and serosal invasion than the other groups of tumours. Patients with uPA(+)/PAI-1(-) tumours had a significantly poorer prognosis than those with uPA(-)/PAI-1(+) tumours. These results indicate that uPA expression is a useful biological prognostic indicator, and that uPA expression is a useful biological prognostic indicator, and that uPA and PAI-1 may play an important part in the tumour progression and metastasis in gastric cancer.lld:pubmed
pubmed-article:8624578pubmed:languageenglld:pubmed
pubmed-article:8624578pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8624578pubmed:citationSubsetIMlld:pubmed
pubmed-article:8624578pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8624578pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8624578pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8624578pubmed:statusMEDLINElld:pubmed
pubmed-article:8624578pubmed:monthFeblld:pubmed
pubmed-article:8624578pubmed:issn0945-6317lld:pubmed
pubmed-article:8624578pubmed:authorpubmed-author:KawamuraTTlld:pubmed
pubmed-article:8624578pubmed:authorpubmed-author:ItoHHlld:pubmed
pubmed-article:8624578pubmed:authorpubmed-author:EndoYYlld:pubmed
pubmed-article:8624578pubmed:authorpubmed-author:SasakiTTlld:pubmed
pubmed-article:8624578pubmed:authorpubmed-author:FujitaHHlld:pubmed
pubmed-article:8624578pubmed:authorpubmed-author:YonemuraYYlld:pubmed
pubmed-article:8624578pubmed:authorpubmed-author:FujimuraTTlld:pubmed
pubmed-article:8624578pubmed:authorpubmed-author:NoseHHlld:pubmed
pubmed-article:8624578pubmed:authorpubmed-author:NojimaNNlld:pubmed
pubmed-article:8624578pubmed:authorpubmed-author:TsuchiharaKKlld:pubmed
pubmed-article:8624578pubmed:issnTypePrintlld:pubmed
pubmed-article:8624578pubmed:volume427lld:pubmed
pubmed-article:8624578pubmed:ownerNLMlld:pubmed
pubmed-article:8624578pubmed:authorsCompleteYlld:pubmed
pubmed-article:8624578pubmed:pagination487-96lld:pubmed
pubmed-article:8624578pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:8624578pubmed:meshHeadingpubmed-meshheading:8624578-...lld:pubmed
pubmed-article:8624578pubmed:meshHeadingpubmed-meshheading:8624578-...lld:pubmed
pubmed-article:8624578pubmed:meshHeadingpubmed-meshheading:8624578-...lld:pubmed
pubmed-article:8624578pubmed:meshHeadingpubmed-meshheading:8624578-...lld:pubmed
pubmed-article:8624578pubmed:meshHeadingpubmed-meshheading:8624578-...lld:pubmed
pubmed-article:8624578pubmed:meshHeadingpubmed-meshheading:8624578-...lld:pubmed
pubmed-article:8624578pubmed:meshHeadingpubmed-meshheading:8624578-...lld:pubmed
pubmed-article:8624578pubmed:meshHeadingpubmed-meshheading:8624578-...lld:pubmed
pubmed-article:8624578pubmed:meshHeadingpubmed-meshheading:8624578-...lld:pubmed
pubmed-article:8624578pubmed:meshHeadingpubmed-meshheading:8624578-...lld:pubmed
pubmed-article:8624578pubmed:meshHeadingpubmed-meshheading:8624578-...lld:pubmed
pubmed-article:8624578pubmed:meshHeadingpubmed-meshheading:8624578-...lld:pubmed
pubmed-article:8624578pubmed:meshHeadingpubmed-meshheading:8624578-...lld:pubmed
pubmed-article:8624578pubmed:meshHeadingpubmed-meshheading:8624578-...lld:pubmed
pubmed-article:8624578pubmed:meshHeadingpubmed-meshheading:8624578-...lld:pubmed
pubmed-article:8624578pubmed:meshHeadingpubmed-meshheading:8624578-...lld:pubmed
pubmed-article:8624578pubmed:year1996lld:pubmed
pubmed-article:8624578pubmed:articleTitlePrognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.lld:pubmed
pubmed-article:8624578pubmed:affiliationThe Second Department of Surgery, School of Medicine, Kanazawa University, Ishikawa, 920 Japan.lld:pubmed
pubmed-article:8624578pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8624578lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8624578lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8624578lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8624578lld:pubmed